Journal
JOURNAL OF CLINICAL NEUROSCIENCE
Volume 16, Issue 6, Pages 854-855Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.jocn.2008.09.005
Keywords
Temozolomide; Glioma; Glioblastoma multiforme
Categories
Ask authors/readers for more resources
Temozolomide (TMZ) is an alkylating agent used in the management of gliomas. Although TMZ is generally safe and acute toxicity is well documented, there are limited data on long-term toxicities. We present three patients with glioma; all patients started on TMZ after having progressed following primary treatment. These patients have continued TMZ for 5 years, 7 years and 8 years respectively. So far they have had no serious side effects. We discuss these patients while raising the question of prolonged TMZ use. Crown Copyright (C) 2008 Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available